A selective type 4 phosphodiesterase inhibitor, T-440, modulates intracellular cyclic AMP level and interleukin-2 production of Jurkat cells

Immunopharmacology

Volumn 38, Issue 3, 1998, Pages 247-252

  Kaminuma, Osamu ^a,b   Mori, Akio ^b   Wada, Kazuteru ^a   Kikkawa, Hideo ^a   Ikezawa, Katsuo ^a   Suko, Matsunobu ^b   Okudaira, Hirokazu ^b  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

cAMP; Cytokine; Jurkat cells; Phosphodiesterase; T cell

Indexed keywords

4 [6,7 DIETHOXY 2,3 BIS(HYDROXYMETHYL) 1 NAPHTHYL] 1 (2 METHOXYETHYL) 2(1H) PYRIDINONE; CYCLIC AMP; FORSKOLIN; INTERLEUKIN 2; PHOSPHODIESTERASE; PHOSPHODIESTERASE IV INHIBITOR; PROSTAGLANDIN E2; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; IMMUNOMODULATION; LEUKEMIA CELL LINE; PRIORITY JOURNAL; T LYMPHOCYTE;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ADJUVANTS, IMMUNOLOGIC; CELL MEMBRANE; CONCANAVALIN A; CYCLIC AMP; CYTOSOL; DINOPROSTONE; FORSKOLIN; HUMANS; INTERLEUKIN-2; JURKAT CELLS; NAPHTHALENES; PHOSPHODIESTERASE INHIBITORS; PYRIDONES;

EID: 0031907015     PISSN: 01623109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0162-3109(97)00071-4     Document Type: Article

References (25)

1. + channel activity in Jurkat cells. Cell. Immunol. 128:1990;385-399.
2. Beavo J.A. Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms. Physiol. Rev. 75:1995;725-748.
3. Benbernou N., Esnault S., Potron G., Guenounou M. Regulatory effects of pentoxifylline on T-helper cell-derived cytokine production in human blood cells. J. Cardiovasc. Pharmacol. 25:1995;S75-79.
4. Bloom T.J., Beavo J.A. Identification of type VII PDE in HUT78 T-lymphocyte cells (Abstract). FASEB J. 8:1994;A372.
5. Chouaib S., Welte K., Mertelsmann R., Dupont B. Prostaglandin E2 acts at two distinct pathways of T lymphocyte activation: Inhibition of interleukin 2 production and down-regulation of transferrin receptor expression. J. Immunol. 135:1985;1172-1179.
6. Essayan D.M., Huang S., Kagey-Sobotka A., Lichtenstein L.M. Effects of nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors on antigen-induced cytokine gene expression in peripheral blood mononuclear cells. Am. J. Respir. Cell. Mol. Biol. 13:1995;692-702.
7. Goodwin J.S., Ceuppens J. Regulation of immune response by prostaglandins. J. Clin. Immunol. 3:1983;295-315.
8. Ichimura M., Kase H. A new cyclic nucleotide phosphodiesterase isozyme expressed in the T-lymphocyte cell lines. Biochem. Biophys. Res. Commun. 193:1993;985-990.
9. Iwasaki T., Kondo K., Kuroda T., Moritani Y., Yamagata S., Sugiura M., Kikkawa H., Kaminuma O., Ikezawa K. Novel selective PDE IV inhibitors as antiasthmatic agents. Synthesis and biological activities of a series of 1-aryl-2,3-bis(hydroxymethyl)naphthalene lignans. J. Med. Chem. 39:1996;2696-2704.
10. Kaminuma O., Mori A., Suko M., Kikkawa H., Katsuo I., Okudaira H. Interleukin-5 production by peripheral blood mononuclear cells of asthmatic patients is suppressed by T-440: Relation to phosphodiesterase inhibition. J. Pharmacol. Exp. Ther. 279:1996;240-246.
11. + T cells inhibits acquisition of ability to produce IFN-γ and IL-2, but not IL-4 and IL-5. J. Immunol. 155:1995;4604-4612.
12. Kennedy M.S., Stobo J.D., Goldyne M.E. In vitro synthesis of prostaglandins and related lipids by populations of human peripheral blood mononuclear cells. Prostaglandins. 20:1980;135-141.
13. Kurland J.I., Bockman R. Prostaglandin E production by human blood monocytes and mouse peritoneal macropharges. J. Exp. Med. 147:1978;115-121.
14. Lewis G.M., Caccese R.G., Heaslip R.J., Bansbach C.C. Effects of rolipram and CI-930 on IL-2 mRNA transcription in human Jurkat cells. Agents Actions. 39:1993;C89-92.
15. Mary D., Aussel C., Ferrua B., Fehlmann M. Regulation of interleukin 2 synthesis by cAMP in human T cells. J. Immunol. 139:1987;1179-1184.
16. Minakuchi R., Wacholtz M.C., Davis L.S., Lipsky P.E. Delineation of the mechanism of inhibition of human T cell activation by PGE2. J. Immunol. 145:1990;2616-2625.
17. Moore A.R., Willoughby D.A. The role of cAMP regulation in controlling inflammation. Clin. Exp. Immunol. 101:1995;387-389.
18. Nicholson C.D., Shahid M. Inhibitors of cyclic nucleotide phosphodiesterase isoenzymes-their potential utility in the therapy of asthma. Pulm. Pharmacol. 7:1994;1-17.
19. 2. J. Immunol. 152:1994;5703-5713.
20. Robicsek S.A., Blanchard D.K., Djeu J.Y., Krzanowski J.J., Szentivanyi A., Polson J.B. Multiple high-affinity cAMP-phosphodiesterases in human T-lymphocytes. Biochem. Pharmacol. 42:1991;869-877.
21. Teixeira M.M., Williams T.J., Hellewell P.G. E-type prostaglandins enhance local oedema formation and neutrophil accumulation but suppress eosinophil accumulation in guinea-pig skin. Br. J. Pharmacol. 110:1993;416-422.
22. + T lymphocytes. Clin. Exp. Allergy. 25:1995;616-624.
23. Thompson W.J., Terasaki W.L., Epstein P.M., Strada S.J. Assay of cyclic nucleotide phosphodiesterase and resolution of multiple molecular forms of the enzyme. Adv. Cyclic Nucl. Res. 10:1980;69-92.
24. Van Wauwe J., Aerts F., Walter H., de Boer M. Cytokine production by phytohemagglutinin-stimulated human blood cells: Effects of corticosteroids, T cell immunosuppressants and phosphodiesterase IV inhibitors. Inflamm. Res. 44:1995;400-405.
25. Wacholtz M.C., Minakuchi R., Lipsky P.E. Characterization of the 3′,5′-cyclic adenosine monophosphate-mediated regulation of IL-2 production by T cells and Jurkat cells. Cell. Immunol. 135:1991;285-298.